SMAD3 and breast cancer: Moreover, ginkgetin treatment upregulated miR-122-5p, leading to specific binding to the GALNT10 3′-untranslated regions, which ultimately reduced Smad3 mRNA and protein levels in MDA-MB-231 breast cancer cells [44].